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Case Report
Propylthiouracil induced ANCA-associated
vasculitis in a 14-year-old girl
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Background: Antineutrophil cytoplasmic antibodies (ANCAs) are the serologic hallmark of ANCA-
associated primary small-vessel vasculitides (AAVs), but these antibodies have also been described in
other autoimmune diseases such as inflammatory bowel diseases. Furthermore, different drugs are linked
to the induction of ANCA, including propylthiouracil (PTU). However progression into clinical overt vasculitis
is less common.
Case-diagnosis/treatment: We describe the case of a young girl with Graves’ disease presenting with
fatigue, fever, episcleritis and arthritis. The unexpected double myeloperoxidase/proteinase 3-ANCA
positivity triggered a multidisciplinary diagnostic work-up and resulted in the diagnosis of a clinically overt
PTU-induced AAV. After PTU-withdrawal and treatment with high-dose corticosteroids, a favorable clinical
and biochemical evolution was obtained.
Conclusions: The use of PTU in the management of hyperthyroidism is not considered first-line treatment in
Europe and is even less commonly used in children. Nevertheless, pediatricians should be aware of the
possibility of PTU-induced AAV, especially in the presence of multiple ANCA reactivities. Therefore, the use
of this drug should be weighed carefully in children.
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Background
Antineutrophil cytoplasmic antibodies (ANCAs) are
the serologic hallmark of ANCA-associated primary
small-vessel vasculitides, with myeloperoxidase (MPO)
and proteinase 3 (PR3) being identified as the two
major target antigens. Other specificities against various
neutrophil components have been demonstrated in
disorders other than ANCA-associated vasculitides
(AAVs) including other autoimmune disorders like
inflammatory bowel disease and infections.1 Further-
more, various drugs have been linked to the induction
of ANCA.1
Propylthiouracil (PTU) and methimazole (MMI)
are antithyroid drugs widely used as first-line treat-
ment in children with Graves’ disease. Within the
class of antithyroid agents, PTU is known to induce
ANCA in 15–64% of patients with Graves’ disease,
but only a minority of these patients show clinical
overt vasculitis. In contrast to Asian countries and
the USA, the use of PTU is less common practice in
the management of hyperthyroidism in Europe.2 In
addition, reporting on PTU-induced AAV in children
is scarce. We report a case of PTU-induced AAV in a
young girl with double MPO/PR3-ANCA positivity,
an uncommon finding that triggered a multidisciplin-
ary diagnostic work-up.
Case-diagnosis/Treatment
A 14-year-old Caucasian girl presented with a one
week history of worsening fatigue and pallor. At the
age of nine she was diagnosed with Graves’ disease
and treated with PTU since. She was euthyroid with
levothyroxine substitution therapy. Besides pallor,
her clinical exam was unremarkable. Palpation of
the thyroid gland was normal. The only abnormal
laboratory finding was profound ferropenic anemia
(Table 1). She denied gastrointestinal symptoms or
blood losses.
Work-up for anemia showed a reticulocyte count
of 3%, normal vitamin B12 and folic acid. Hemolysis
and hemoglobinopathies were excluded. Haptoglobin
and liver function tests with direct and total bilirubin
and lactate dehydrogenase levels were normal. Blood
smear demonstrated poikilocytosis and few fragmen-
ted red blood cells; the direct Coombs test was
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negative. Furthermore, both fecal occult blood test
and radioisotope Meckel’s scan were negative. A
diagnosis of Iron deficiency anemia was made and the
patient received oral iron treatment.
Four weeks later she developed low grade fever,
arthritis of the left ankle and elbow without evidence
for septic arthritis. She was referred to the pediatric
rheumatology department of our centre for further
diagnostic work-up.
Physical examination revealed pallor, unilateral red
eye, defined as episcleritis by the ophthalmologist,
and swelling of the right elbow without warmth or
tenderness. On further inquiry, occasional morning
stiffness and one previous episode of uveitis and
episcleritis were withheld. In addition, two episodes of
minor hemoptysis occurred, suggesting pulmonary
vasculitis as well. There was no history of mucocuta-
neous abnormalities and family history for autoim-
mune diseases was negative. Laboratory investigations
showed significant changes for the following para-
meters: hemoglobin (9.2 g/dl), erythrocyte sedimenta-
tion rate (21 mm/hour), creatinine (1.25 mg/dl), urine
protein/creatinine (0.66 g/g) and hematuria (300/ml)
(Table 1). Complement factor C3 and C4 were within
the normal range, as were thyroid function tests.
Serologic work-up showed the presence of antinuclear
antibodies (homogeneous 3z/4z, anti-dsDNA nega-
tive, anti-ENA negative) and a mixed perinuclear/
cytoplasmic ANCA pattern (intensity 5z) with MPO-
and PR3-ANCA positivity (Table 1). Further testing,
demonstrated no additional ANCA-reactivities (anti-
bodies against lactoferrin, elastase, cathepsin G, and
BPI were tested). Renal biopsy showed pauci-immune
focal segmental glomerulonephritis with cellular cres-
cents in 4 out of 12 glomeruli.
As double ANCA positivity is uncommon and
frequently associated with drug-induced AAV,2 PTU-
induced AAVwas suspected. PTUwas withdrawn and
high-dose oral corticosteroids were started (2 mg/
kg/day) with satisfactory clinical and biochemical
response (Fig. 1). Upon follow-up, no more arthritis
appeared and exercise tolerance improved signifi-
cantly. Anemia resolved and renal function amelio-
rated. In parallel, a decline in MPO/PR3-ANCA
positivity was observed and seven months after
cessation of PTU therapy, ANCA antibody titers
normalized. Apart from the cushingoid facial char-
acteristics and increased glucose levels, she did not
experience other side effects of the high-dose systemic
corticosteroids. A careful corticosteroid tapering sche-
dule was followed based on clinical and biochemical
disease evolution. She was treated with oral steroids
for a period of nine months. Recently, our patient
underwent thyroidectomy because of relapse of
hyperthyroidism.
Discussion
In patients treated with antithyroid drugs, the
reported prevalence of ANCA varies from 4 to 46%
with clinical overt AAV in 0–1.4% of these patients.2
For PTU, ANCA-positivity is seen in 15–64% of
patients and systemic vasculitis in approximately one-
fourth to one-third of them,2,3 with similar findings in
adult as well as pediatric patient populations.2
Figure 1 Biochemical evolution of laboratory parameters
upon PTU-withdrawal. Dx, diagnosis; ANCA, antineutrophil
cytoplasmatic antibodies; MPO, myeloperoxidase (normal
,5 IU/ml); PR3, proteinase 3 (normal ,3 IU/ml); Hb, hemo-
globin (normal 12–16 g/dl); PCR, protein-to-creatinine ratio
(normal ,0.20 g/g creatinine).
Table 1 Laboratory data
First presentation At diagnosis After 3 months CS Normal range
Haemoglobin (g/dl) 6.9 9.2 12.0 12.0–16.0
MCV (fl) 67.1 84.5 84.8 82.3–96.4
Iron (mg/dl) 14 67 178 50–150
Ferritin (mg/dl) 43 137 94 13–150
ESR (mm/hour) 20 21 5 ,10
CRP (mg/l) 2.1 2.0 ,0.6 ,5.0
Serum creatinine (mg/dl) 0.77 1.25 0.96 0.50–0.95
Urine protein/creatinine (g/g) 0.18 0.66 0.30 ,0.20
Haematuria (RBC/ml) 2000 300 180 ,25
MPO-ANCA (IU/ml) N/A 15.0 8.1 ,5.0
PR3-ANCA (IU/ml) N/A 27.0 5.1 ,3.0
Note: MCV, mean corpuscular volume; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RBC, red blood cells; PCR,
protein-to-creatinine ratio; ANCA, antineutrophil cytoplasmatic antibodies; MPO, myeloperoxidase; PR3, proteinase 3; N/A, not
available; CS, corticosteroids.
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In contrast to primary vasculitis, in which MPO-
ANCA and PR3-ANCA are presumed mutually
exclusive, multiple target antigens can be simulta-
neously encountered in PTU-induced AAV.1,2
Moreover, this observation appears to be associated
with an increased risk of the development of clinical
signs.3 The pathogenesis of PTU-induced AAV is not
yet fully understood. PTU decreases thyroid hor-
mone production by inhibiting the enzym thyroid
peroxidase. The nucleotide and amino acid structures
of the latter and MPO approach a similarity of 50%,
which could explain an interaction between PTU and
the target antigens of ANCA, in particular MPO,
contributing to the development of PTU-induced
AAV. On the one hand, PTU was found to alter the
structure of MPO by decreasing its oxidation activity,
which may serve as a neoantigen.2 On the other hand,
MPO itself might affect the structure of PTU and
transform it into immunogenic cytotoxic metabolites,
triggering ANCA production.
As only one-third of patients with PTU-induced
ANCA develop clinical vasculitis,2 several studies
were performed to identify risk factors for the
development of clinical signs. First, the antigenic
specificity of ANCA seems to play a role. Gao and
colleagues3 showed that most patients with clinical
overt PTU-induced vasculitis show multiple ANCA
reactivities (92.6%) and/or MPO-ANCA positivity
(92.6%). In both cases, these antibody profiles were
significantly more common in patients with overt
vasculitis compared to those without symptoms (mul-
tiple reactivities: 92.6 versus 31.6%; MPO-ANCA:
92.6 versus 36.8%).3 Secondly, the immunological
characteristics of the MPO-ANCA antibodies might
be of particular importance. Both titers as well as
avidity of MPO-ANCA were significantly higher in
patients with clinical overt PTU-induced vasculitis
compared to asymptomatic patients and epitope
specificity against MPO-ANCA was different.4
Thirdly, long-term exposure to PTU was found to
be associated with an increased incidence of PTU-
induced AAV although there are no clear data on the
cumulative threshold dose of PTU that would induce
vasculitis.2
At the time of diagnosis, our patient experienced
long-term exposure to PTU (5 years) and showed
serum ANCA against multiple targets including
MPO. She fulfilled at least three out of six risk
criteria for the development of overt PTU-induced
vasculitis as proposed by Chen and Colleagues.2
Furthermore, episcleritis as well as renal and pulmo-
nary involvement were observed through the disease
course.
Clinical manifestations of PTU-induced AAV are
similar to those of primary AAV. However, disease
severity is generally milder and the overall prognosis is
better. In patients with organ involvement, the
duration of immunosuppressive therapy is still incon-
clusive, but might be shorter than that in primary
AAV. Moreover, maintenance therapy might not be
necessary.2 Despite discontinuation of the offending
drug, immunosuppressive therapy and clinical and
biochemical normalisation of vasculitis, ANCA might
remain positive for up to multiple years.2
Fortunately PTU-induced AAV in patients is rare.
PTU and MMI have been widely used for the
treatment of hyperthyroidism in both children and
adult, with minor side effects being itching, rash,
urticaria, joint pain and swelling, fever, myalgia,
paresthesia, vertigo and lymphadenopathy. Over the
past 60 years of PTU and MMI use, reports of PTU-
related liver failure and death have accumulated.5 In
contrast, this problem has not been reported with
MMI use in children. Perhaps because of these
concerns, there has been an important reduction in
PTU use in the pediatric population over the past
decade and it is suggested that PTU should no longer
be used as first line treatment for Graves’ diseases in
children.
Conclusion
In summary, we report a case of drug-induced AAV
in a 14-year-old girl during PTU treatment for
Graves’ disease. She presented with fatigue secondary
to anemia, fever, episcleritis and pauciarticular
arthritis. During the disease course, she developed
glomerulonephritis and mild pulmonary vasculitis.
Diagnostic work-up revealed a PTU-induced AAV as
confirmed by the clinical and laboratory improve-
ment on drug withdrawal. The presence of multiple
target ANCA antigens is a risk factor for developing
clinically overt vasculitis. Because of accumulation
reports of PTU-related liver failure and death, PTU is
no longer considered as a first-line treatment for
Graves’ disease in children.
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